Kleinhans, S.; Lang, G.; Goujon-Ginglinger, C.
Chemical characterization of smoke-free products relies on both validated quantitative methods for specific analytes and screening methods such as non-targeted differential screening (NTDS). The latter approach identifies compositional differences between complex samples without prior knowledge of the differential compounds. However, for a fraction of compounds with variable concentrations between two samples in an NTDS study, the observed differences are due in part to intrinsic variability in the aerosol collection and analytical methods. As a result, a subset of the reported compounds—particularly those with low fold changes—are specious and not reproducible between studies. The goal of this work was to derive an appropriate fold-change cut-off value to limit false-positive discoveries to a reasonable number.
A dataset was acquired by applying seven liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry methods to aerosol samples produced by the Tobacco Heating System (THS) 3.0., and this dataset was augmented with simulated data points. A fold-change cut-off value of 1.25 was calculated, such that if a THS product was subjected to a comparison to itself, only 2.5 % of all analytical features would be above the cut-off value.
Considering only compounds increased by > 25 % in the sample vs. the comparator improves the statistical and scientific relevance of NTDS results and shifts the focus to compounds with differences that have greater toxicological relevance.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.